Esperion Hopes CVOT Will Help Drive Nexletol/Nexlizet’s Market Uptake
Executive Summary
The drugs have been slow to catch on since approval more than two years ago, but results showing reduction in cardiovascular events could help it gain traction.
You may also be interested in...
NewAmsterdam Takes Another Step Toward CETP Inhibitor Success
Positive Phase II data indicate that obicetrapib, a cholesterol-lowering drug licensed from Amgen, could succeed where prior drugs in the class have consistently failed for more than a decade.
Stock Watch: Filling In The Blanks In Clinical Trial Result Announcements
If a clinical trial is positive, with safety and efficacy that trounces the competition, why be coy about the details?
Esperion Aiming For 50% Commercial Coverage For Nexletol
The company hopes to sidestep payer restrictions and patient abandonment by launching the cholesterol-lowering medicine at a palatable price point in line with where branded statins were before patent expiry.